saved
Request for Proposal
Status: RFP is Closed

Drug Discovery Seed or Target in the Hematology Therapeutic Area

Request Number
RFP_2019_0133
Due Date
Sep 16
Program Manager

Opportunity

Joint research and licensing

 

Timeline

Within 1 year before the start of the joint research

 

Financials

Negotiable, depending on the proposed content

 

How to  Apply
  • Click "Respond", complete the form to the extent possible, and submit along with other attachment files available. 
  • After creating your account for NineSights, your draft will be automatically saved and you can resume later from "Control Center". Please note you do not submit confidential information at this process.
SOLUTION PROVIDER HELP DESK
If you have any questions or request, please feel free to contact us at: phd2@ninesigma.com 
RFP was closed on
Oct 2019

RFP Title

 

Drug Discovery Seed or Target in the Hematology Therapeutic Area
RFP Description

NineSigma, representing Kyowa Kirin Co., Ltd. (https://www.kyowa-kirin.com/index.html), seeks a collaborative partner with drug discovery seed or target in the hematology therapeutic area.  Ultimately, through a collaboration with the promising organization, the client aims to develop innovative drugs that meet unmet medical needs in the following four hematology therapeutic areas.

Key Success Criteria

Target Diseases and Challenges

The following (1) to (4) are target diseases. The client seeks proposals that can achieve any of the described challenges for each disease.

(1) Primary myelofibrosis (PMF)

(1)-1 Improvement of the overall survival

for transplant-ineligible patients

(1)-2 Improvement of the success rate in allogeneic transplantation

 

(2) Graft-versus-host disease (GVHD)

(2)-1 GVHD treatment or prevention that does not reduce the Graft Versus Leukemia effect (GVL effect)

(2)-2 GVHD treatment or prevention for patients with steroid resistance

 

(3) Aplastic Anemia (AA)

(3)-1 Improvement of QOL in transplant-ineligible patients (such as recovery of blood cell counts that enables a patient to have the same QOL as before symptom onset)

 

(4) Idiopathic thrombocytopenic purpura (ITP)

(4)-1 Development of drugs that are effective for relapsed and/or refractory patients

 

Drug Discovery Seed

  • Type: Antibody, biologics, peptide, nucleic acid, or low molecular weight compound
  • Development Stage: From identification of a drug discovery seed to preclinical studies

 

Drug Discovery Target

  • A proposal that includes in vivo or in vitro data showing the validity as a target is desired, however, proposals that are at the conceptual stages are also welcomed.
Approaches not of Interest

Approaches Not of Interest

The following approaches are not of interest:

  • Proposal for only a disease model without presenting any drug targets
  • Diagnosis biomarker that cannot be drug discovery target.
  • Approach to target the thrombopoietin (TPO) receptor for aplastic anemia (AA)
  • Approach to target the immune system and the TPO receptor for idiopathic thrombocytopenic purpura (ITP)
Items to be Submitted

Items to be Submitted

NineSights, the platform of NineSigma’s Open Innovation community, allows you to manage all your proposals. Please contact the Solution Provider Help Desk phd2@ninesigma.com for assistance about registration and proposal submission.

Proposal may include the following items along the response form shown by clicking the “Respond” button. 

  • Targeted disease and challenge  (multiple choice)
  • Overview of the proposal
    • In case of drug discovery seed: Type of compounds (antibodies, biologics, nucleic acid, low molecular weight compounds), characteristics, novelty
    • In case of drug discovery target:  Relationships between the target and the disease, and the novelty
  • R&D stage
    • In case of drug discovery seed: Development stage (identification of a drug discovery seed, drug efficacy tests in a laboratory, and preclinical tests)
    • In case of drug discovery targets: Research stage (concept, cellular level, animal level)
  • Evidence and data that show efficacy and validity of drug efficacy test
  • Request for partnership
  • Status of intellectual property concerning the proposed technology
  • Past research achievements (related patents and papers)
  • Organization Overview

 

Notes on Response

Proposal shall have clear points and should not include confidential information. Supplemental files may be submitted in addition to the proposal.

 

Response Evaluation

The client will evaluate all responses with the following criteria.

  • Overall scientific and technical merit
  • Approach to proof of concept or performance
  • Economic potential of concept
  • Realism of the proposed plan (action items, timeline, roles, deliverables, cost estimation)
  • Potential for proprietary position
  • Respondents’ capability and related experiences

 

Anticipated Project Process

After reviewing submitted proposals, the client possibly ask clarifying questions before selecting the most suitable candidates for collaboration. The client will select best candidates through evaluations. During the selection process, the client may execute NDA with selected respondents, seek further information disclosure, and discuss specific development targets or potential opportunities.

The client will execute necessary agreements with the selected respondents and move to the advanced development phase. Specifics of any collaboration will be determined through consultation with the concerned parties.

Preferred Collaboration Types
Area of Interest